<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Head-to-head Superiority over Dulaglutide: Innovent&#8217;s Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024	</title>
	<atom:link href="https://9krapalm.com/head-to-head-superiority-over-dulaglutide-innovents-phase-3-clinical-trial-dreams-2-of-mazdutide-in-chinese-patients-with-type-2-diabetes-were-orally-presented-at-easd-2024/feed/" rel="self" type="application/rss+xml" />
	<link>https://9krapalm.com/head-to-head-superiority-over-dulaglutide-innovents-phase-3-clinical-trial-dreams-2-of-mazdutide-in-chinese-patients-with-type-2-diabetes-were-orally-presented-at-easd-2024/</link>
	<description>เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm</description>
	<lastBuildDate>Thu, 12 Sep 2024 00:49:43 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.1</generator>
</channel>
</rss>
